Effective
Accumulation and Management of Clinical Data
The effective accumulation and management
of high quality clinical data is of paramount importance to the
pharmaceutical and associated clinical development industries. Following
recent high profile cases, the pharmaceutical industry must learn
how to rise to the challenges of improved safety quality on marketed
drugs as demanded by regulators and patients through continual assessment
and demonstrating safety around and after launch through effective
post-marketing studies.
This eyeforpharma report will review ways in which good planning
and use of e-technology can maximise return on investment in late
phase clinical trials - by increasing efficiency of data collection
and reducing time to analysis and commercialisation for streamlined
safety reporting.
This report will
look at:
- Effective ways to accumulate clinical trial and post
marketing surveillance data for improved quality of safety
on your marketed drugs
- Evaluate the pros and cons of e-tools for
fast and effective late phase clinical data collection
- Techniques for ensuring data is interpreted efficiently
and evolving information on the benefits and risks is
evaluated for streamlined safety reporting
Fill in the form below now to receive
your copy:
(* = required)
|
